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Promises and controversies in the management 
of low-grade glioma
Low-grade gliomas (LGGs) are a heterogeneous group of relatively
slow-growing primary tumors of astrocytic and/or oligodendroglial
origin. Peak incidence occurs in the second and third decade of
life. Many patients will present with easily controlled seizures and
will remain stable for many years, whereas others may progress
rapidly, with increasing neurological symptoms, to a higher-grade
tumor. Although morphologically indistinguishable at diagnosis,
the time interval to progression varies considerably from a few
months to several years. To date treatment options were limited to
surgery when feasible, and radiotherapy and palliative chemo-
therapy at recurrence. Oligodendroglioma with specific molecular
changes (allelic loss on chromosomes 1p and 19q) have been
recognized over the last decade to be a distinct subgroup with a
better prognosis and a particular sensitivity to chemotherapy [1].
New chemotherapy agents against malignant glioma are currently
in development, and temozolomide, a novel alkylating agent, has
been approved for the treatment of recurrent malignant (high-
grade) glioma [2].
In this issue, two prospective phase II trials report radiological
and clinical response to single agent temozolomide chemotherapy
in patients with LGG, albeit based on quite different patient popu-
lations. A British study included patients with stable or progressive
disease and who have not received any prior chemo- or radiotherapy
[3]. In the study from Italy patients were required to have progres-
sive disease, over two-thirds of their patients had received prior
radiotherapy and one-third had also received previous chemo-
therapy [4]. No repeat histological confirmation was performed,
but on repeat surgery anaplastic features were present in eight of
16 operated patients. Contrast enhancement on MRI, another sign
of possible malignant transformation, was present in 60% of
patients. Interestingly, although the objective response rates are
quite different between the two trials (10% in the British trial com-
pared with 47% in the Italian trial), when minor responses are also
considered, the tumor regression rates are 57% and 56%, respect-
ively. There is inherent difficulty with response assessment in the
brain, where tumor cannot always be distinguished from associated
edema and normal tissue. In some patients the radiological
response was only demonstrated after several months of therapy.
Sophisticated imaging techniques like positron emission tomo-
graphy (PET) using amino acid traces or functional imaging (e.g.
MR spectroscopy) may be of help in the future.
Progression-free survival in the British study was 94% and 76%
at 1 and 2 years, respectively, while, despite the higher response
rate, in the Italian trial more than half of the patients had pro-
gressed within 1 year, reflecting the different patient populations.
In LGG initial and long-term symptom control and quality of life
are end points as important as tumor shrinking on imaging. Both
studies document a clinical benefit with improvement in seizure
control in about half of the patients.
The British study had to be closed prematurely short of only a
few additional patients. The authors indicate ‘availability of the
investigational agent’ as the reason. Conducting clinical research
is becoming increasingly difficult. The desire of patients to be
treated with a new agent paired with a strong pressure by the phar-
maceutical industry to prescribe new and expensive drugs hamper
accrual into trials. New techniques or therapeutic options will thus
never be fully explored nor properly evaluated. Additional obstacles
come from the health authorities and regulatory bodies warranting
specific additional insurance coverage and industrial funding for
most protocols, while similar treatments outside clinical trials can
be freely prescribed.
Where do these reports lead us? Should patients with LGG now
be considered for primary chemotherapy? At initial diagnosis
many patients do not require any specific therapy, but rather
careful psychological guidance. Surgery should be attempted for
precise diagnosis and in cases where a complete resection can be
achieved [5, 6]. Based on two randomized trials, the European
Organization for Research and Treatment of Cancer (EORTC)
provides us with a useful prognostic score for identifying patients
with the worst prognosis who are most likely to benefit from
therapy [7]. Age ≥40 years, astrocytic tumor type, tumor size
>6 cm, tumor crossing the midline and neurological deficit at
diagnosis were identified as independent prognostic factors, and
the presence of three or more of these factors was associated with
an unfavorable prognosis.
For patients with unfavorable prognostic factors radiotherapy
currently remains the established treatment option. Two random-
ized trials have examined the dose of radiotherapy and there
appears to be no survival benefit for total doses >45–50 Gy [8, 9].
Of concern with frequently ill-defined and diffusely infitrating
tumors are the required large radiation volumes, which may lead
to debilitating late sequelae in patients who will survive for many
years [10, 11]. Highly conformal radiation techniques (e.g.
intensity-modulated radiotherapy) combined with co-registered
MR and PET imaging may limit the amount of normal brain tissue
irradiated [12–14].
The timing of radiation therapy was the object of a randomized
trial comparing immediate radiotherapy with delayed radiotherapy
at progression [15]. Although time to progression was longer in
the immediate therapy group, progressing patients whose radio-
therapy had been delayed could be successfully salvaged, and sur-
vival was identical in both arms. Two-thirds of the progressing
patients subsequently received radiation accounting for only 38%
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of the patients in the observation group. Thus, radiotherapy could
be withheld in almost two-thirds of patients for >5 years.
Whether primary chemotherapy with the currently available
drugs allows the delay of radiation and its sequelae remains to be
demonstrated. Secondary malignancies are to be expected with
long-term alkylating agent chemotherapy. A randomized trial
comparing standard radiotherapy to chemotherapy will be con-
ducted by the EORTC and the National Cancer Institute of
Canada. In contrast to the present reports, temozolomide will be
administered as a low-dose continuous schedule. Chronic drug
exposure may be critical for response in a slow-growing indolent
tumor. In this trial patients will only be treated at documented pro-
gression or in the presence of unfavorable prognostic factors.
Patients will be prospectively stratified for histological and for
molecular markers (1p loss). This allows the identification of sub-
groups of patients who are more likely to benefit from one or from
the other treatment modality.
Management of LGG remains a challenging task. More precise
definition of tumor entities, including also specific molecular
markers, is necessary to identify patients in need of a more aggres-
sive treatment strategy. Evaluation of the known prognostic fac-
tors by an experienced multidisciplinary team is the basis for any
treatment recommendation or for watchful waiting. The role of
chemotherapy and new biological agents currently in develop-
ment needs to be established in well-designed clinical trials.
Long-term toxicity is of concern in a disease where patients may
live for many years.
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